Login to Your Account

Galapagos Seeks Partner on Heels of Strong RA Drug Data

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 30, 2011
LONDON – Galapagos NV reported strong efficacy data from a Phase IIa proof-of-concept study of its selective Janus kinase 1 (JAK 1) inhibitor GLP0634 in rheumatoid arthritis and said it is now in partnering discussions.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription